Litiumklorid Lidco: Uses, Dosage & Side Effects
A lithium chloride indicator solution used for transpulmonary lithium dilution cardiac output monitoring in critically ill patients
Litiumklorid Lidco is a sterile lithium chloride solution (0.15 mmol/mL) used exclusively in hospital settings as an indicator substance for measuring cardiac output through the transpulmonary lithium dilution technique. It is not a therapeutic medication; rather, it is a diagnostic tool used with the LiDCO hemodynamic monitoring system. A small bolus of the solution is injected intravenously, and a lithium-sensitive sensor on a peripheral arterial line measures the resulting dilution curve to calculate how much blood the heart pumps per minute. This information is critical for guiding treatment decisions in critically ill patients in intensive care units and during major surgery. Litiumklorid Lidco requires a prescription and must be administered only by trained healthcare professionals with appropriate monitoring equipment.
Quick Facts: Litiumklorid Lidco
Key Takeaways
- Litiumklorid Lidco is a diagnostic indicator solution, not a therapeutic drug. It is used exclusively for measuring cardiac output (how much blood the heart pumps per minute) in critically ill patients using the LiDCO hemodynamic monitoring system.
- The lithium dilution technique is a minimally invasive alternative to pulmonary artery catheter thermodilution, requiring only a peripheral venous and peripheral arterial line to measure cardiac output accurately.
- The diagnostic dose of lithium chloride (0.15–0.3 mmol per injection) is far below the therapeutic range used for psychiatric conditions and produces negligible pharmacological effects at these concentrations.
- Litiumklorid Lidco must not be used in patients already receiving therapeutic lithium therapy (e.g., for bipolar disorder), as background lithium levels interfere with measurement accuracy.
- Non-depolarizing neuromuscular blocking agents (e.g., atracurium, rocuronium) can interfere with the lithium sensor and may produce inaccurate cardiac output readings; timing of injections should be coordinated accordingly.
What Is Litiumklorid Lidco and What Is It Used For?
Litiumklorid Lidco contains lithium chloride at a concentration of 0.15 mmol/mL. It is classified as a diagnostic agent rather than a therapeutic medication, meaning it is not given to treat any disease or condition. Instead, it serves a critical role in hemodynamic monitoring — the measurement and assessment of blood flow and pressures within the cardiovascular system. Specifically, it is used as the indicator substance for the LiDCO (Lithium Dilution Cardiac Output) monitoring system, a technology widely used in intensive care units (ICUs) and operating theatres around the world.
Cardiac output — the volume of blood the heart pumps per minute — is one of the most important parameters in the management of critically ill patients. Inadequate cardiac output means the body's organs and tissues are not receiving sufficient oxygen and nutrients, which can lead to organ failure and death if not corrected promptly. Accurate and timely measurement of cardiac output allows intensivists and anesthesiologists to make informed decisions about fluid therapy, vasoactive medications (drugs that affect blood vessel tone), and inotropic agents (drugs that increase heart contractility).
The LiDCO system was developed as a less invasive alternative to the traditional pulmonary artery catheter (PAC, also known as the Swan-Ganz catheter), which had been the gold standard for cardiac output measurement for decades. While the PAC requires insertion of a catheter through the right heart into the pulmonary artery — a procedure that carries risks of arrhythmias, pulmonary artery rupture, and infection — the LiDCO system requires only a peripheral venous cannula (or central venous catheter) for injection and a peripheral arterial catheter for detection. This substantially reduces the invasiveness and associated risks of the monitoring procedure.
The measurement works on the indicator dilution principle, first described by Stewart and Hamilton in the early 20th century. A precisely known quantity of lithium chloride is injected as a rapid bolus through a venous line. The lithium ions travel through the right side of the heart, through the pulmonary circulation, through the left side of the heart, and out into the systemic arterial circulation, where they are detected by a lithium-selective electrode attached to an existing peripheral arterial line (typically in the radial artery). The sensor generates a concentration-time curve, and cardiac output is calculated using the Stewart-Hamilton equation: cardiac output is inversely proportional to the area under the dilution curve. A high cardiac output produces a lower, broader curve (because the indicator is more diluted), while a low cardiac output produces a taller, narrower curve.
Once the LiDCO system has been calibrated using a lithium dilution measurement, it can then provide continuous beat-to-beat cardiac output monitoring through a proprietary pulse power analysis algorithm called PulseCO. This algorithm analyzes the arterial pressure waveform to estimate stroke volume and cardiac output on a continuous basis. Periodic recalibration with additional lithium boluses is recommended to maintain accuracy, particularly after significant hemodynamic changes such as fluid administration, vasopressor dose changes, or position changes.
It is important to understand that Litiumklorid Lidco is not the same as lithium used to treat bipolar disorder. Therapeutic lithium (lithium carbonate or lithium citrate) is taken in much larger daily doses over long periods. The tiny single-bolus doses of lithium chloride used for cardiac output monitoring (0.15–0.3 mmol) are far too small to produce any psychiatric, neurological, or other therapeutic effect.
Clinical Settings Where Litiumklorid Lidco Is Used
Litiumklorid Lidco and the LiDCO system are employed in a variety of clinical settings where accurate cardiac output monitoring is needed to guide patient management:
- Intensive care units (ICUs): For critically ill patients with sepsis, septic shock, cardiogenic shock, or other conditions causing hemodynamic instability, where cardiac output data is essential for titrating fluids and vasoactive drugs.
- During major surgery: Particularly high-risk cardiac surgery, major abdominal or thoracic surgery, and transplant surgery, where real-time hemodynamic data helps the anesthesiologist optimize the patient's circulatory status.
- Emergency departments: In selected cases involving acute heart failure, massive hemorrhage, or other acute circulatory emergencies where rapid assessment of cardiac output can influence immediate management decisions.
- Goal-directed therapy (GDT): The LiDCO system is frequently used in perioperative goal-directed therapy protocols, where fluid administration and vasoactive drugs are titrated to achieve specific cardiac output and oxygen delivery targets, which has been shown in clinical trials to reduce complications and hospital stay after major surgery.
What Should You Know Before Using Litiumklorid Lidco?
Because Litiumklorid Lidco is a diagnostic agent administered exclusively in hospital settings by healthcare professionals, patients themselves do not need to make decisions about when or how to use it. However, understanding the precautions and contraindications is important for both clinicians and patients who wish to be informed about the procedures being performed.
Contraindications
There are specific situations in which Litiumklorid Lidco should not be used:
- Patients on therapeutic lithium: Patients already receiving lithium therapy (e.g., lithium carbonate for bipolar disorder) have elevated baseline serum lithium levels. The lithium-sensitive sensor cannot distinguish between the background therapeutic lithium and the indicator bolus, which would render the cardiac output measurement inaccurate. Alternative methods of cardiac output monitoring should be used in these patients.
- Known hypersensitivity: Patients with a known allergy or hypersensitivity to lithium chloride or any of the excipients in the formulation should not receive this product, although such allergic reactions are extremely rare.
- First trimester of pregnancy: Lithium is classified as potentially teratogenic, particularly during the first trimester when it has been associated with a slightly increased risk of cardiac malformations (Ebstein's anomaly). Although the diagnostic doses used are extremely small, the use of Litiumklorid Lidco should be avoided during the first trimester unless absolutely necessary and no alternative monitoring is available.
Warnings and Precautions
Several important precautions should be observed when using Litiumklorid Lidco:
- Renal impairment: Lithium is excreted primarily by the kidneys. In patients with severe renal impairment (significantly reduced glomerular filtration rate), lithium clearance is decreased. Although a single diagnostic dose is unlikely to cause problems, repeated doses over a short period could theoretically lead to lithium accumulation. The number of injections should be limited in patients with severe renal failure, and serum lithium levels should be monitored if multiple calibrations are needed.
- Sodium-depleted patients: Lithium reabsorption in the renal tubules is enhanced in states of sodium depletion. Patients who are severely sodium-depleted may retain lithium longer than expected. This is generally not clinically significant at diagnostic doses but should be considered if multiple boluses are administered.
- Pediatric use: Limited data are available on the use of lithium dilution cardiac output monitoring in neonates and small children. The dose must be appropriately adjusted for body weight, and the smaller blood volumes in pediatric patients mean that even small doses produce proportionally higher peak lithium concentrations. Clinical judgment should guide use in this population.
- Accurate measurement requirements: For reliable results, the injection must be given as a rapid, smooth bolus. The arterial sensor must be properly calibrated and positioned. The patient should be hemodynamically stable during the measurement (significant rhythm disturbances, valvular regurgitation, or intracardiac shunts can affect accuracy).
Pregnancy and Breastfeeding
Therapeutic lithium use during pregnancy has been associated with a small but real increase in the risk of congenital cardiac malformations, particularly Ebstein's anomaly (a malformation of the tricuspid valve). Although this association was established with chronic therapeutic doses that maintain serum levels of 0.6–1.2 mmol/L, and the single diagnostic bolus of Litiumklorid Lidco produces only a transient peak far below these levels, caution is still advised. During the first trimester, alternative cardiac output monitoring methods (such as echocardiographic techniques or pulse contour analysis calibrated by other means) should be preferred when available.
In the second and third trimesters, the risk-benefit ratio may favor use of Litiumklorid Lidco if cardiac output monitoring is clinically essential and no suitable alternative is available. The decision should be made by the treating physician in consultation with the patient.
Lithium is known to pass into breast milk. However, given the extremely small doses used for diagnostic purposes and the rapid distribution and elimination of the indicator bolus, the amount of lithium that would appear in breast milk following a single diagnostic injection is negligible. Breastfeeding does not need to be interrupted after a cardiac output measurement with Litiumklorid Lidco.
Litiumklorid Lidco is a hospital-only medication that must be administered by healthcare professionals trained in its use and in the operation of the LiDCO hemodynamic monitoring system. It should never be self-administered or used outside of a clinical setting with appropriate monitoring equipment.
How Does Litiumklorid Lidco Interact with Other Drugs?
Because Litiumklorid Lidco is given as a small, single-use diagnostic bolus rather than as ongoing therapy, traditional drug-drug interactions (where two drugs affect each other's metabolism or action) are less relevant than with therapeutic medications. However, there are several important interactions that can affect either the accuracy of the cardiac output measurement or the handling of the lithium indicator by the body.
Major Interactions
The following interactions are considered clinically significant and may require avoidance of the lithium dilution technique or careful timing of the injection:
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Therapeutic lithium (lithium carbonate, lithium citrate) | Elevated baseline lithium levels make indicator dilution curve measurement impossible | Absolute contraindication; use alternative cardiac output monitoring |
| Non-depolarizing neuromuscular blocking agents (atracurium, cisatracurium, rocuronium, vecuronium, pancuronium) | These agents contain quaternary ammonium compounds that can cross-react with the lithium-sensitive electrode, producing a falsely elevated signal | Measurement should be performed before administration of muscle relaxants or after sufficient time has elapsed for washout; consult LiDCO system manual for specific timing |
Minor Interactions
The following interactions are generally of minor clinical significance with diagnostic doses but should be considered in specific situations, particularly when multiple lithium boluses are administered:
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| NSAIDs (ibuprofen, diclofenac, ketorolac) | Reduce renal lithium clearance by decreasing prostaglandin-mediated renal blood flow | Negligible at single diagnostic doses; may be relevant with repeated boluses in patients with renal impairment |
| ACE inhibitors / ARBs (enalapril, losartan) | May reduce renal lithium excretion | Clinically insignificant at diagnostic doses |
| Thiazide diuretics (hydrochlorothiazide, bendroflumethiazide) | Increase lithium reabsorption in the proximal tubule, reducing lithium clearance | Unlikely to be significant with single diagnostic doses; relevant only with repeated injections |
| Loop diuretics (furosemide, bumetanide) | Variable effect on lithium clearance; may initially increase then decrease clearance as sodium depletion develops | Generally not significant; consider sodium status in patients on aggressive diuretic therapy |
It is important to note that these interactions primarily affect the renal excretion of the lithium indicator dose. Since cardiac output measurement depends on the first-pass arterial dilution curve (occurring within seconds of injection) rather than on the total body clearance of lithium, these interactions do not affect the accuracy of the measurement itself. They are relevant only insofar as they affect how quickly the lithium is eliminated from the body after the measurement is complete.
What Is the Correct Dosage of Litiumklorid Lidco?
Litiumklorid Lidco is always administered by a healthcare professional as part of a cardiac output monitoring procedure. The dosing is determined by the clinical team based on the LiDCO system requirements and the patient's clinical situation. Patients do not self-administer this product.
Adults
Standard Adult Dose
The recommended dose for a single lithium dilution cardiac output measurement in adults is 0.15 to 0.3 mmol of lithium chloride, equivalent to 1 to 2 mL of the 0.15 mmol/mL solution. The injection is given as a rapid bolus (over approximately 2–3 seconds) through a central venous catheter or peripheral venous cannula.
Multiple measurements may be performed during a patient's ICU stay or surgical procedure. The LiDCO system typically recommends an average of 3 consecutive measurements for initial calibration. Recalibration may be performed as clinically indicated, usually every 4–8 hours or after significant hemodynamic changes.
In a typical clinical scenario, the total daily lithium exposure from diagnostic use is substantially less than the daily dose used in psychiatric therapy. For example, three calibration boluses of 0.3 mmol each provide a total of 0.9 mmol of lithium — compared to typical therapeutic lithium doses of 12–24 mmol per day for bipolar disorder. The diagnostic doses are therefore approximately 25–50 times lower on a per-day basis.
Children
Pediatric Dose
There is limited published data on the use of lithium dilution cardiac output monitoring in pediatric patients. When used in children, the dose should be adjusted for body weight, typically in the range of 0.002 to 0.004 mmol/kg. The lower blood volume in children means that standard adult doses would produce inappropriately high peak lithium concentrations. Pediatric use should be guided by institutional protocols and the LiDCO system manufacturer's recommendations for pediatric patients.
Elderly
Elderly Patients
No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients are more likely to have reduced renal function, which may slow lithium elimination. The number of repeated injections should be considered carefully in elderly patients with known or suspected renal impairment. Standard adult dosing (0.15–0.3 mmol per injection) is generally appropriate.
Patients with Renal Impairment
Renal Impairment
Lithium is eliminated almost entirely by renal excretion. In patients with moderate to severe renal impairment (eGFR <30 mL/min/1.73m²), lithium clearance is significantly reduced. A single diagnostic dose is unlikely to cause problems, but the total number of injections should be limited in these patients. If multiple calibrations are required over a prolonged period, serum lithium levels should be checked to ensure they remain well below the therapeutic range (<0.4 mmol/L). Alternative cardiac output monitoring methods should be considered for patients requiring frequent recalibration who have severe renal impairment.
Missed Dose
The concept of a "missed dose" does not apply to Litiumklorid Lidco. It is a single-use diagnostic agent administered as needed for cardiac output measurement. If a measurement is not performed at a planned time, it can simply be performed later when clinically appropriate. There is no scheduled dosing regimen that requires catching up.
Overdose
Accidental overdose with Litiumklorid Lidco is extremely unlikely in clinical practice, as the solution is prepared in small, pre-measured ampoules and administered by trained personnel. However, if an excessive dose were to be given, the management would depend on the amount administered. At doses several times the recommended diagnostic dose, serum lithium levels should be monitored. If levels approach or enter the therapeutic range (0.6–1.2 mmol/L), standard lithium toxicity monitoring and management protocols should be followed. This would include monitoring of renal function, fluid balance, and electrolytes, with sodium chloride infusion to promote lithium excretion. Hemodialysis effectively removes lithium and would be indicated in cases of significant toxicity, though this scenario is virtually unheard of with diagnostic lithium chloride.
If lithium toxicity is suspected following accidental overdose (symptoms include tremor, nausea, vomiting, diarrhea, confusion, and in severe cases cardiac arrhythmias or seizures), contact the treating physician or local poison control center immediately. Standard intensive care monitoring and treatment should be instituted.
What Are the Side Effects of Litiumklorid Lidco?
Because Litiumklorid Lidco is administered in very small diagnostic doses that produce transient blood lithium concentrations well below the therapeutic range, true drug-related side effects are uncommon. The vast majority of patients who undergo lithium dilution cardiac output monitoring experience no adverse effects attributable to the lithium chloride injection itself. The side effects that have been reported or are theoretically possible are listed below by frequency category.
It is important to distinguish between side effects caused by the lithium chloride solution and complications related to the overall monitoring procedure (such as arterial line complications), which are attributable to the vascular access devices rather than to the indicator substance.
Uncommon
May affect up to 1 in 100 patients
- Transient mild irritation or warmth at the injection site
- Brief metallic taste during or immediately after injection
- Transient sensation of warmth or flushing (due to the bolus injection itself)
Rare
May affect up to 1 in 1,000 patients
- Nausea (transient, resolves spontaneously)
- Mild local venous irritation at the injection site
- Transient mild tremor (extremely rare and self-limiting)
Theoretical / Not Known Frequency
Based on pharmacological knowledge rather than reported cases
- Lithium accumulation with repeated doses in patients with severe renal impairment (could theoretically lead to lithium-related effects such as tremor, polyuria, or thyroid changes if serum levels reach the therapeutic range)
- Allergic or hypersensitivity reaction to lithium chloride or excipients (not documented in published literature but theoretically possible with any injectable substance)
- Cardiac arrhythmia from extremely rapid or inadvertent high-dose injection (not documented with recommended doses)
The safety profile of lithium dilution cardiac output monitoring has been evaluated in numerous clinical studies over more than two decades. In the original validation studies by Linton et al. and subsequent large clinical series, no significant adverse events were attributed to the lithium chloride indicator injection itself. The consensus in the critical care literature is that transpulmonary lithium dilution is a safe and well-tolerated technique for cardiac output measurement.
Patients who receive multiple lithium dilution measurements during their ICU stay (sometimes daily for several days) have been studied, and serum lithium levels have been found to remain well below the therapeutic range even after many consecutive days of use, provided renal function is not severely impaired. In one study of critically ill patients receiving an average of 8 lithium boluses over several days, the mean serum lithium level was 0.02 mmol/L, compared to the therapeutic range of 0.6–1.2 mmol/L used in psychiatric practice.
If you experience any side effects during or after a cardiac output measurement, inform the medical team immediately. Healthcare professionals should report any suspected adverse reactions to their national pharmacovigilance authority (e.g., the MHRA in the UK, EMA in Europe, or FDA MedWatch in the US).
How Should You Store Litiumklorid Lidco?
Litiumklorid Lidco is a hospital-only product, and its storage is managed by the hospital pharmacy and the clinical departments that use it. Patients do not need to store this medication themselves. However, the following storage conditions apply:
- Temperature: Store below 25°C at room temperature. Do not refrigerate or freeze the solution, as temperature extremes may affect the stability and sterility of the product.
- Light protection: Keep in the original outer carton to protect from light. Prolonged exposure to direct light may degrade the product.
- Single use: Litiumklorid Lidco ampoules are for single use only. Any unused solution remaining after a measurement should be discarded according to hospital policy for pharmaceutical waste. Do not save partially used ampoules for later use.
- Visual inspection: Before use, the solution should be inspected visually. It should be a clear, colorless solution. Do not use if the solution appears cloudy, contains particles, or if the ampoule or packaging is damaged.
- Expiry date: Do not use after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
- Keep out of reach of children: As with all medications, store in a secure location inaccessible to children.
The hospital pharmacy typically manages stock rotation to ensure that ampoules are used before their expiry date. In emergency situations where cardiac output monitoring is urgently needed, the availability and condition of Litiumklorid Lidco stock should be verified as part of the routine equipment and drug checks in the ICU or operating theatre.
What Does Litiumklorid Lidco Contain?
The formulation of Litiumklorid Lidco is deliberately simple, as befits a diagnostic indicator solution that needs to be chemically inert (apart from its indicator function) and safe for intravenous injection.
Active Substance
The active substance is lithium chloride (LiCl) at a concentration of 0.15 mmol/mL (equivalent to approximately 6.36 mg/mL of lithium chloride, or approximately 1.04 mg/mL of elemental lithium). Lithium chloride is a simple inorganic salt that dissolves readily in water to produce lithium cations (Li+) and chloride anions (Cl−). It is the lithium cation that is detected by the lithium-selective electrode on the arterial sensor of the LiDCO system.
Excipients
The solution contains water for injections as the sole excipient. The formulation may be adjusted to physiological pH and osmolality using small amounts of hydrochloric acid or sodium hydroxide. The product is preservative-free, which is standard for single-use injectable products designed for intravenous administration.
Packaging
Litiumklorid Lidco is supplied in clear glass ampoules, each containing a precisely measured volume of solution. The ampoules are packed in a cardboard carton with the product information leaflet. The packaging is designed to protect the ampoules from mechanical damage and light exposure during storage and transport.
Each mL of Litiumklorid Lidco solution contains 0.15 mmol lithium chloride in water for injections. The solution is sterile, preservative-free, and intended for single intravenous bolus injection as a cardiac output indicator.
How Does Lithium Dilution Cardiac Output Monitoring Work?
Understanding how the lithium dilution technique works helps to appreciate why Litiumklorid Lidco is formulated the way it is and why certain precautions are necessary. The technique is an application of the indicator dilution method, one of the fundamental approaches to measuring blood flow in physiology and clinical medicine.
The Indicator Dilution Principle
The indicator dilution method was first described by George N. Stewart in 1897 and later refined mathematically by William F. Hamilton in the 1930s. The core principle is simple: if a known quantity of a detectable substance (the indicator) is introduced into a flowing stream, the degree to which it is diluted by the time it reaches a downstream detection point is inversely related to the flow rate. Higher flow dilutes the indicator more, producing a lower peak concentration and a broader curve; lower flow dilutes it less, producing a higher peak concentration and a narrower curve.
In cardiovascular physiology, the "flowing stream" is the blood flowing through the heart and great vessels. By injecting an indicator into the venous system and detecting it in the arterial system, one can measure the total blood flow through the heart — i.e., cardiac output. The mathematical relationship is expressed by the Stewart-Hamilton equation:
CO = m / (∫ C(t) dt)
Where CO = cardiac output, m = the quantity of indicator injected, and the integral represents the area under the concentration-time curve measured at the detection point. This equation shows that cardiac output is equal to the amount of indicator divided by the area under its dilution curve.
Why Lithium?
Lithium was chosen as the indicator substance for several important reasons:
- Not normally present in blood: Unlike sodium, potassium, or calcium, lithium is not a normal constituent of human blood (except in patients receiving therapeutic lithium). This means there is essentially zero background signal, and even very small amounts of injected lithium can be accurately detected.
- Ion-selective electrode technology: Lithium-selective electrodes can be manufactured that are highly specific for lithium ions and can measure lithium concentrations rapidly and accurately in flowing blood, even in the presence of other electrolytes.
- Safety at diagnostic doses: The doses of lithium chloride required for cardiac output measurement (0.15–0.3 mmol) are far below those that produce pharmacological effects, making it very safe for diagnostic use.
- No first-pass loss: Unlike some other potential indicators, lithium is not metabolized, bound to proteins, or sequestered by the lungs during its first pass through the cardiopulmonary circuit. This means the full injected dose arrives at the arterial sensor, ensuring accurate measurement.
- No need for central venous catheter: Unlike thermodilution (which requires a thermistor in the pulmonary artery), the lithium injection can be given through a peripheral venous cannula, making the technique less invasive.
The LiDCO System
The LiDCO hemodynamic monitoring system consists of three main components:
- Lithium chloride indicator (Litiumklorid Lidco): The injection solution used for calibration.
- Lithium-sensitive sensor: A flow-through electrode that attaches to the existing peripheral arterial line. It contains a lithium-selective membrane that generates a voltage proportional to the lithium concentration in the blood flowing through it.
- LiDCO monitor: A bedside computer that records the signal from the lithium sensor, constructs the dilution curve, applies the Stewart-Hamilton equation to calculate cardiac output, and then uses the PulseCO algorithm to provide continuous beat-to-beat cardiac output monitoring from the arterial pressure waveform.
The PulseCO algorithm uses the area under the systolic portion of the arterial pressure waveform (pulse power) as a surrogate for stroke volume. Once calibrated with a lithium dilution measurement, the system can track changes in cardiac output continuously without further lithium injections. Recalibration is recommended periodically (typically every 4–8 hours) or when significant hemodynamic changes occur that might alter the relationship between pulse power and stroke volume.
Comparison with Other Cardiac Output Monitoring Methods
| Method | Invasiveness | Calibration | Key Advantage |
|---|---|---|---|
| Lithium dilution (LiDCO) | Minimally invasive (peripheral venous + arterial line) | Lithium indicator bolus | No pulmonary artery catheter needed; continuous monitoring via PulseCO |
| Pulmonary artery catheter thermodilution | Highly invasive (PAC through right heart) | Cold saline bolus | Gold standard; also measures pulmonary artery pressures and mixed venous O₂ |
| Transpulmonary thermodilution (PiCCO) | Moderately invasive (CVC + femoral arterial line) | Cold saline bolus via CVC | Provides additional volumetric parameters (GEDV, EVLW) |
| Echocardiography (TTE/TEE) | Non-invasive (TTE) or semi-invasive (TEE) | Not required | Non-invasive; provides structural and functional cardiac information |
| Uncalibrated pulse contour (FloTrac/Vigileo) | Minimally invasive (arterial line only) | Not required (algorithm-based) | Simplest setup; no indicator injection needed |
The LiDCO system occupies an important niche in the hemodynamic monitoring landscape: it is less invasive than pulmonary artery catheterization or transpulmonary thermodilution, but it provides calibrated continuous cardiac output monitoring that is generally more accurate than uncalibrated pulse contour methods. It is particularly well-suited for perioperative goal-directed therapy and for patients who need continuous cardiac output monitoring but do not require a pulmonary artery catheter.
Frequently Asked Questions
Litiumklorid Lidco is a lithium chloride indicator solution used exclusively in hospitals for measuring cardiac output — the volume of blood the heart pumps per minute. It is injected intravenously as a small bolus dose and detected by a lithium-sensitive sensor on a peripheral arterial line. The resulting concentration-time curve allows the LiDCO hemodynamic monitoring system to calculate cardiac output using the lithium dilution technique. It is a diagnostic tool, not a therapeutic medication.
Lithium dilution cardiac output monitoring works on the indicator dilution principle (Stewart-Hamilton method). A small, precisely measured bolus of lithium chloride solution (typically 0.15–0.3 mmol) is injected through a venous line. The lithium passes through the heart and lungs, then reaches a lithium-selective electrode attached to a peripheral arterial catheter. The sensor measures the lithium concentration over time, producing a dilution curve. Cardiac output is inversely proportional to the area under this curve.
No. While both contain the lithium ion, they serve entirely different purposes. Therapeutic lithium (lithium carbonate or lithium citrate) is prescribed in much higher doses for the long-term treatment of bipolar disorder. Litiumklorid Lidco is a very small single-use intravenous bolus used solely as a diagnostic indicator for measuring cardiac output. The doses used for cardiac output monitoring (0.15–0.3 mmol) are far below those that produce pharmacological effects.
No. Patients on therapeutic lithium already have elevated baseline serum lithium levels, which would interfere with the accuracy of the lithium dilution measurement. The lithium-sensitive sensor cannot distinguish between indicator lithium and pre-existing therapeutic lithium in the blood. Alternative methods of cardiac output monitoring, such as thermodilution or echocardiography, should be used in these patients.
Side effects from Litiumklorid Lidco are rare because the diagnostic doses used are far below the therapeutic range. Potential effects include transient injection site irritation, a brief metallic taste, or mild warmth/flushing. In patients with severe renal impairment, repeated doses could theoretically lead to lithium accumulation. The technique has been used safely in clinical practice for over two decades.
The LiDCO system uses transpulmonary lithium dilution to calibrate continuous cardiac output monitoring. A bolus of lithium chloride solution is injected intravenously, and a lithium-selective sensor on a peripheral arterial line detects the lithium as it passes through. The system calculates cardiac output from the dilution curve. Once calibrated, the system tracks beat-to-beat changes using pulse power analysis (PulseCO algorithm), requiring only periodic recalibration.
References
- Linton RA, Band DM, Haire KM. A new method of measuring cardiac output in man using lithium dilution. British Journal of Anaesthesia. 1993;71(2):262-266.
- Linton RA, Jonas MM, Tibby SM, et al. Cardiac output measured by lithium dilution and transpulmonary thermodilution in patients in a paediatric intensive care unit. Intensive Care Medicine. 2000;26(10):1507-1511.
- Cecconi M, Rhodes A. Validation of continuous cardiac output technologies: consensus still awaited. Critical Care. 2009;13(3):159.
- Costa MG, Della Rocca G, Chiarandini P, et al. Continuous and intermittent cardiac output measurement in hyperdynamic conditions: pulmonary artery catheter vs. lithium dilution technique. Intensive Care Medicine. 2008;34(2):257-263.
- Pearse RM, Harrison DA, MacDonald N, et al. Effect of a perioperative, cardiac output–guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review (OPTIMISE trial). JAMA. 2014;311(21):2181-2190.
- Cecconi M, De Backer D, Antonelli M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Medicine. 2014;40(12):1795-1815.
- European Medicines Agency. Summary of Product Characteristics: Litiumklorid Lidco. Available from EMA product database.
- LiDCO Ltd. LiDCOplus Hemodynamic Monitor – Instructions for Use. London, UK.
- Mckendry M, McGloin H, Sabber D, et al. Randomised controlled trial assessing the impact of a nurse delivered, flow monitored protocol for optimisation of circulatory status after cardiac surgery. BMJ. 2004;329(7460):258.
- Hamilton TT, Huber LM, Sunshine ME. PulseCO: a less-invasive method to monitor cardiac output from arterial pressure after cardiac surgery. Annals of Thoracic Surgery. 2002;74(4):S1408-S1412.
Editorial Team
Medical Writer
iMedic Medical Editorial Team — Specialists in Intensive Care Medicine and Clinical Pharmacology
Medical Reviewer
iMedic Medical Review Board — Independent panel of critical care and hemodynamic monitoring experts
Evidence Standard
Level 1A — Based on systematic reviews, randomized controlled trials, and international consensus guidelines (ESICM, ESC)
Independence
No commercial funding — Independent medical editorial content with no pharmaceutical company sponsorship
This article was written and reviewed by medical professionals with expertise in critical care medicine, hemodynamic monitoring, and clinical pharmacology. All content follows the iMedic Editorial Standards and the GRADE evidence framework.